Cyclooxygenase-2 expression in XXXX : correlation with poor outcome after chemotherapy.

@entity1 @entity5 @entity900 @entity150 @entity3
OBJECTIVES: Cycylooxygenase-2 (Cox-2) has been shown to play a significant role in the carcinogenesis of various @entity1 @entity5 . Recent experimental work suggests that Cox-2 expression may reduce the cytotoxic effects of chemotherapy and radiation therapy. We examined Cox-2 expression in @entity150 and its relationship to clinicopathologic factors, survival data, and outcome in @entity1 receiving @entity900 -based chemotherapy. METHODS: In 157 @entity1 after cystectomy for @entity150 , Cox-2 was assessed immunohistochemically; 62 @entity1 had received chemotherapy, either adjuvant or for @entity3 . Results were correlated with clinical data, survival and outcome of chemotherapy. RESULTS: Cox-2 expression was present in 131 @entity1 (83.4%). Expression did not correlate with @entity5 stage and histologic grade, but was significantly related to histologic subtype (TCC vs. SCC, p=0.038). Survival analysis showed no relation between Cox-2 expression and overall and disease-free survival; however, in the subgroup of 62 @entity1 who received chemotherapy, strong Cox-2 expression significantly correlated with poor overall survival (p=0.01). CONCLUSIONS: High expression of Cox-2 in @entity150 @entity1 receiving chemotherapy was significantly associated with shorter survival. Further studies are warranted to clarify if combining chemotherapy with Cox-2-inhibition has an impact on response and survival rates.
